BioSpace News Archive

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced first quarter 2021 financial results and provided an update on the cytisinicline clinical development program.

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2021 financial results and provided an update on recent progress.

Marrone Bio Innovations, Inc., an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, released an update letter to shareholders from Chief Executive Officer Kevin Helash.

Augmedix, Inc. (OTCQX: AUGX), a leading provider of remote medical documentation and live clinical support, today reported financial results for the three months ended March 31, 2021.

BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, published its fourth quarter and full year financial results for the year ended December 31, 2020 and provided a business update.

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced its financial and operating results for the three months ended March 31, 2021.

Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for its second quarter and first half of fiscal 2021 ending March 31, 2021 (“Q2” and “H1”), with record sales and earnings, plus progress upon its strategic goals.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted priority review for the company’s New Drug Application (NDA), which was submitted in March

Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that the updated phase I clinical data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody,

Australian pharmaceutical group Phebra congratulates the Australasian Leukaemia and Lymphoma Group on the release of their abstract EP433 at the virtual European Hematology Association 2021 Conference.